{
  "id": 878546,
  "title": "Lantern Q2 2026 slides: operating loss drops 25%, LP-300 data strengthens",
  "url": "https://urgent.news/2026/08/14/lantern-q2-2026-slides-operating-loss-drops-25-lp-300-data-strengthens",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-14T14:19:36.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/lantern-q2-2026-slides-operating-loss-drops-25-lp300-data-strengthens-93CH-4861101"
  },
  "original_language": "en",
  "account": "On August 14, 2026, Lantern Pharma (LTRN) released its Q2 2026 financial results, revealing a 25% decrease in operating losses and promising clinical breakthroughs for its lead oncology candidate LP-300. The company's stock fell 3.23% to $2.55 following the announcement. Despite a wider net loss, Lantern Pharma's operating expenses reduced significantly due to a 42% decline in research and development spending to $1.8 million. However, non-cash warrant expenses widened the net loss by $3.6 million. The company's balance sheet showed a decrease in cash reserves from $10.1 million to $7.4 million. Lantern Pharma emphasized the need for additional funding, aiming to pursue capital raises and collaborations. The Q2 results highlighted LP-300's progress in non-small cell lung cancer trials, with extended treatment duration benefiting certain patients. Additionally, Lantern Pharma secured regulatory approval for its investigational product LP-184 in a Phase 1b/2 bladder cancer trial in Denmark. The company's strategic separation of Open-Medicine AI into a standalone entity was also announced, positioning itself to capitalize on the growing AI drug discovery market.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}